高剂量糖皮质激素治疗COVID-19是否获益?
本文针对Edalatifard等人的随机对照试验提出方法学质疑,指出对照组死亡率(43%)高于RECOVERY试验对照组(26%),且样本量计算依据不足。作者认为开放标签设计可能导致干预组获得更好的支持治疗,从而影响生存差异,高剂量糖皮质激素目前不推荐用于重症COVID-19肺炎。
要点
- 对照组死亡率43%高于RECOVERY试验的26%,可能受支持治疗差异影响
- 开放标签设计可能使干预组获得更好的支持治疗
- 样本量计算引用哮喘、慢阻肺等研究,依据不充分
核心结论
- 高剂量糖皮质激素目前不推荐用于治疗重症COVID-19肺炎。
- 对Edalatifard等研究的生存差异提出质疑,可能源于开放标签导致的支持治疗差异。
研究设计与样本
- 本文为对Edalatifard等人随机对照试验的评论信,无原始研究设计。
- 原文提及干预组死亡率低,对照组死亡率43%。
主要发现
- 对照组死亡率43%高于RECOVERY试验对照组的26%。
- ARDS(急性呼吸窘迫综合征)未出现、患者未插管,对照组死亡率与病情严重程度不匹配。
- 机械通气COVID-19相关ARDS死亡率50%或以下,随时间从42%改善至25%。
关键数值与推荐
- 高剂量糖皮质激素目前不推荐用于重症COVID-19肺炎。
临床怎么用
- 临床不应将高剂量糖皮质激素作为重症COVID-19肺炎的常规推荐治疗。
- 解读相关试验结果时需考虑开放标签设计可能带来的支持治疗差异偏倚。
局限性
- 样本量计算依据不充分,引用哮喘、慢阻肺和术前研究作为参考。
- 开放标签设计可能使干预组获得更好的支持治疗,影响生存差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-dose glucocorticoids are not currently recommended for treating severe COVID-19 pneumonia https://bit.ly/39VQ3O8 We read with interest the article by Edalatifard et al. [1], and we congratulate them for performing a randomised controlled trial amidst the ongoing pandemic. We have a few concerns regarding the methods and interpretation of the current study. While the intervention group's mortality is low, the mortality in the control group is disproportionately high for the severity of illness (acute respiratory distress syndrome (ARDS) not present, patients not intubated). The mortality in ARDS due to coronavirus disease 2019 (COVID-19) among mechanically ventilated patients is 50% or less, and it has improved over time from 42% to 25% [2, 3]. The mortality in the current study's control arm (43%) was worse than the mortality in the control arm of the RECOVERY trial (26%) [4]. The survival difference between the two study groups may be due to the better supportive care provided to the intervention arm due to the trial's unblinded nature. Also, the justification provided for the sample size is inadequate. The authors have cited studies using methylprednisolone in asthma, COPD and pre-operative patients as references for the sample size calculation.
引用
- Muthu V, Sehgal IS, Prasad KT, et al. Is high-dose glucocorticoid beneficial in COVID-19? Eur Respir J. 2021. PMID: 33509962. doi:10.1183/13993003.00065-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。